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Abstract
Background: A case series of the cardiac magnetic resonance imaging findings in seven adult
Alström patients.
Methods: Seven patients from the National Specialist Commissioning Group Centre for Alström
Disease, Torbay, England, UK, completed the cardiac magnetic resonance imaging protocol to
assess cardiac structure and function in Alström cardiomyopathy.
Results: All patients had some degree of left and right ventricular dysfunction. Patchy mid wall
gadolinium delayed enhancement was demonstrated, suggesting an underlying fibrotic process.
Some degree of cardiomyopathy was universal. No evidence of myocardial infarction or fatty
infiltration was demonstrated, but coronary artery disease cannot be completely excluded. Repeat
scanning after 18 months in one subject showed progression of fibrosis and decreased left
ventricular function.
Conclusion: Adult Alström cardiomyopathy appears to be a fibrotic process causing impairment
of both ventricles. Serial cardiac magnetic resonance scanning has helped clarify the underlying
disease progression and responses to treatment. Confirmation of significant mutations in the
ALMS1 gene should lead to advice to screen the subject for cardiomyopathy, and metabolic
disorders.
Introduction
Alström syndrome is an autosomal recessive disorder
caused by mutations in the ALMS1 gene (OMIM 203800)
and is known to affect over 450 sufferers worldwide [1,2].
The gene is located on chromosome 2p13 and codes for a
protein linked with the centrosome, though its precise
function is unknown [3,4]. Many different mutations of
the gene have been described but so far numbers have
been too small to uncover genotype-phenotype correla-
tions [5]. The diagnosis should be considered by ophthal-
mologists and geneticists in children with early onset
retinal dystrophy, particularly when accompanied by any
other feature of the syndrome such as insulin resistance
and obesity, sensorineural hearing loss, or cardiomyopa-
thy in infancy or adolescence [2]. Other features which
may present later include short stature, chronic renal and
hepatic dysfunction, bladder instability, early onset type 2
diabetes, and secondary hypothyroidism, hypogonadism
in males, hypertriglyceridaemia, and kyphoscoliosis. The
wide range of possible comorbidities in Alström subjects
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can reduce quality and length of life. Early diagnosis will
afford the opportunity to introduce effective therapies for
heart failure, diabetes, renal impairment, and hyperlipi-
daemia. This is particularly true of cardiomyopathy,
which presents acutely in childhood in 45% with poten-
tially fatal results if unrecognised, and recurs or develops
de novo in 65% in adolescence [6].
The aetiology and pathophysiology of cardiomyopathy in
Alström are incompletely understood. Echo studies have
reported dilated cardiomyopathy [7] while a smaller study
incorporating tissue Doppler imaging (TDI) found a
restrictive pattern [8]. A small autopsy series of 5 patients
demonstrated myocardial fibrosis. [6]
Early diagnosis of cardiac impairment with imaging has
been problematic. There are inherent technical difficulties
with echocardiographic scanning in Alström patients due
to characteristic body habitus with markedly increased
subcutaneous body fat, kyphoscoliosis and pulmonary
disease[9,10]. Echocardiography lacks the inter-study
reproducibility to enable early detection of left ventricular
changes in an individual. The assessment of the impact of
this syndrome on the right ventricle is severely limited by
the inability of echocardiographic scaaning to adequately
visualize the right ventricle. Other techniques, such as
MUGA and PET nuclear imaging, provide poor spatial res-
olution and incur significant radiation exposure in young
patients requiring serial studies. Cardiac magnetic reso-
nance imaging (CMR) offers the opportunity to acquire
high temporal resolution movie images in any desired
plane independent of body habitus and free of radiation.
CMR imaging allows the detection of sub-endocardial,
mid wall or epicardial processes. The high reproducibility
enables subtle changes to be detected in serial studies and
offers the promise of tracking the natural history and
investigating the influence of interventions [11-14]. We




Torbay District General Hospital, South Devon NHS
Trust, is the National Specialised Commissioning Group
centre for Alström syndrome. The CMR scans were clini-
cally indicated in 7 of the 25 Alström subjects in the adult
clinic to follow up echocardiographic abnormalities. They
took place between 2007 and 2009 in the Royal Devon
and Exeter Hospital NHS Foundation Trust.
Seven Alström patients (4 male, ages 19 to 43 years)
underwent at least one cardiac magnetic resonance imag-
ing scan. Three of the adults had cardiomyopathy in
infancy, two of whom were receiving treatment for active
adult onset cardiac failure. All were insulin resistant
defined by a serum C peptide level of >1500 pmol/L, one
hour after a high carbohydrate meal (Table 1).
Thyroid and gonadal function were corrected and stable
for at least 3 months at the time of scanning. All received
metformin but not glitazones and their usual cardiac
medications. Chronic kidney disease stage 1 or 2 was
present in 5 of the subjects.
-Quoted blood results and blood pressure are taken from
the quarterly clinic prior to the CMR scan.
-Due to the visual and hearing sensory deficit these
patients experience, each patient was coached in breath
holding in response to tactile cues.
CMR imaging protocol
All patients underwent CMR using a Siemens Avanto 1.5
T scanner with a cardiac coil. Static transaxial black blood
(HASTE) images were acquired as well as T1 and T2
weighted thin transaxial slices, with and without fat satu-
ration. Left ventricular function was assessed by acquiring
a stack of short axis cine images as previously described
[15,16]. Diastolic function was assessed by acquiring
through plane velocity encoded images at the level of the
mitral valve. First pass perfusion images were performed
in three planes using 0.05 mcg/kg of gadolinium (Magne-
vist; Schering-Bayer). An additional dose of Gadolinium
was given to provide a total of 0.2 mmol/kg and short and
long axis late enhancement images acquired after 15 mins
using a 2D TurboFLASH (fast low angled shot) sequence
(8 mm slice thickness, 2 mm gap, α = 23°, trigger 2
(unless bradycardic when trigger 1 used), number of seg-
ments 25, the TI adjusted for optimal nulling, 250 to 350
ms) [17]. Where present, artefacts were excluded using
phase swaps and/or long axis cuts. A whole ventricle 3D
turboFLASH sequence was also used as a back-up.
Transaxial slices were acquired through the liver, both in
and out of phase to document fatty infiltration.
Data Values
Normal values were adjusted for age, gender and body
surface area, using the standard reference values estab-
lished by the Royal Brompton Hospital [18]. 95% Confi-
dence intervals are quoted for 20–29 yrs as no data
available for ages than 20 yrs.
Results
All 7 patients successfully completed the protocol.
TABLE 2: Cardiac MR results from the Alström patient
series.Orphanet Journal of Rare Diseases 2009, 4:14 http://www.ojrd.com/content/4/1/14
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Anatomical imaging
All patients displayed normal situs with normal gross
architecture of the heart and great vessels. There was a
marked increase in adipose tissue in all cases. (figure 1)
Morphological imaging
No patients displayed intra-myocardial high signal on T1,
T2 stir images (figure 2) There was obvious high signal
epicardial fat deposition that was appropriately nulled on
fat saturation imaging, but no infiltration of the left or
right heart myocardium. This would suggest there was no
fluid or fatty infiltration of the myocardium. There were
no areas consistent with calcium infiltration of the myo-
cardium.
Functional imaging
A spectrum of functional abnormalities was noted, with 4
of the seven patients having dilated left ventricular end
systolic volumes. All patients had some degree of left ven-
tricular dysfunction and 5 patients displayed right ven-
tricular dysfunction. (Additional file 1). There was a mild
Table 1: Characteristics of the Alström patients studied.
N o r m a l  V a l u e s 1 2 34567
A g e  y r s 3 7 2 4 4 31 93 92 62 3
Gender M F M F M F M
BMI <25 47 36 34 33 32 29 29
Genetically confirmed AS heterozygote yes yes yes yes yes yes
Infantile cardiomyopathy no yes no no yes yes no
Blood Pressure 134/56 90/60 112/72 110/56 145/90 100/64 132/81
eGFR 72 57 58 >90 35 44 >90
Ejection Fraction on CMR >55% 61 25 40 60 59 55 50
Clinical failure in last 12 months no yes no no no yes no
NTBNP ng/L <150 24 108 65 14 279 495 6
Triglycerides mmol/L <1.5 7.3 2.6 8.8 2.3 4.0 4.0 1.95
Chol:HDL 5.4 5.6 8.3 4.3 4.6 8.5 6.72
HBA1C % 4.0–6.1 11.0 8.5 9.4 5.2 16.8 6.2 5.2
Transaxial image of the thorax at the level of the heart illus- trating the typical degree of sub-cutaneous and epicardial adi- pose tissue; hence the difficulty in imaging by echo (Patient 1) Figure 1
Transaxial image of the thorax at the level of the 
heart illustrating the typical degree of sub-cutaneous 
and epicardial adipose tissue; hence the difficulty in 
imaging by echo (Patient 1).Orphanet Journal of Rare Diseases 2009, 4:14 http://www.ojrd.com/content/4/1/14
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reduction in left ventricular myocardial mass in most
patients, when corrected for body surface area.
Specific segmental wall motion analysis revealed systolic
regional wall motion abnormalities even in those patients
with preserved left ventricular volumes and reasonable
function.(Additional file 1)
Perfusion imaging
Patients displayed patchy mid-wall perfusion abnormali-
ties that corresponded with areas of delayed enhancement
following gadolinium. The sub-endocardium was notice-
ably spared. The perfusion abnormalities were most prev-
alent in the mid and basal septum which was independent
of the thickness of the myocardium. Given the nature of
the thin wall of the right ventricle it was not possible to
accurately assess perfusion abnormalities in this territory.
Delayed Enhancement imaging
Four of the seven patients displayed some degree of mid
wall late enhancement, with a preference for the basal lat-
eral and mid septal walls. Interestingly, three of the seven
patients also displayed some degree of right ventricular
enhancement. (figure 3)
Follow up studies
Two subjects had further studies one year later, subject 1
to assess effects of change in therapy, and subject 6
because of progression from NYHA heart failure grade 1 to
3.
In subject 1 all the cardiac MR parameters have remained
unchanged. In subject 6 there was a striking increase in
cardiac fibrosis and decrease in all parameters of cardiac
Examples of different sequences for the same short axis slice Figure 2
Examples of different sequences for the same short 
axis slice.
T1 image T2 image
Diastolic cine frame Systolic cine frame
Areas of hyper-enhancement following gadolinium Figure 3
Areas of hyper-enhancement following gadolinium.
RV
Septum
Diastolic and systolic frames of one short axis cine image on  initial and follow up scans, showing an increase in end diasto- lic and end systolic volume and reduced ejection fraction at  follow up Figure 4
Diastolic and systolic frames of one short axis cine 
image on initial and follow up scans, showing an 
increase in end diastolic and end systolic volume and 
reduced ejection fraction at follow up.
Follow up scan
Initial scan
Systole DiastoleOrphanet Journal of Rare Diseases 2009, 4:14 http://www.ojrd.com/content/4/1/14
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function (figure 4). This has led to preparation for cardiac
transplantation in subject 6.
Liver fatty infiltration
There was a heterogeneous expression of diffuse fatty infil-
tration. One patient had marked segmental infiltration
(Additional file 1, patient 2).
Discussion
The frequent coexistence of obesity, insulin resistance,
glucose intolerance, hypertension, dyslipidaemia and
renal dysfunction in the syndrome [19] has led to the sug-
gestion that these potent cardiovascular risk factors lead to
early sub-endocardial infarction with progressive loss of
myocardial tissue and function. Despite the presence of
impaired ventricular function no patient had evidence of
myocardial infarction. Due to the demanding nature of
the protocol it was not felt appropriate at this stage to add
adenosine stress perfusion. Although patchy rest per-
fusion defects were seen that correlate with areas of fibro-
sis, the lack of a formal stress test means that the presence
of myocardial ischaemia was not assessed. Nevertheless,
no patient displayed any sub-endocardial late enhance-
ment suggestive of myocardial infarction and high-resolu-
tion late enhancement CMR allows small areas of sub-
endocardial infarction to be visualised [20]. However our
subjects are relatively young and the lack of stress testing
means that coronary atheroma which might contribute to
cardiac dysfunction cannot be excluded.
Five of the seven patients displayed mid wall hyper-
enhancement of the left ventricle. Since gadolinium can-
not enter live cells, the late enhancement represents late
accumulation of gadolinium in areas of increased extra-
cellular space, classically areas of apoptosis and fibrosis.
The finding that all patients had some degree of cardiac
fibrosis suggests that cardiac failure is related to degree of
myocardial involvement. Subject 2 with clinically severe
heart failure and most extensive CMR evidence of fibrosis
had the highest HbA1c level, longest duration of diabetes
(14 years), and persistent cardiac dysfunction from
infancy.
In this study there was no suggestion of high signal fatty
deposition in the myocardium despite obvious high sig-
nal epicardial fat, even in the patients suffering the worse
cardiac function. This lack of myocardial fatty deposits
occurred despite all but one of the patients displaying dif-
fuse fatty infiltration of the liver.
A consequence of our findings is that co-morbidities in
the syndrome and factors favouring progression to cardiac
dysfunction, which might independently worsen cardiac
function, should be sought and treated early. The combi-
nation of mixed dyslipidaemia, insulin resistance, diabe-
tes, renal impairment and hypertension is very strongly
linked to premature atherosclerosis, especially coronary
artery disease in the general population. This set of disor-
ders, known to occur frequently in Alström subjects
should be assessed and treated energetically, even though
coronary artery disease may not yet have developed in
many of this young group of patients. Again the finding of
significant mutations in the ALMS1 gene would encour-
age surveillance for coronary risk factors and treatment
with hypolipidaemic, insulin sensitising and hypotensive
therapies where indicated.
This is of importance to geneticists as continued search for
phenotype-genotype correlations could lead to more
accurate prognosis for Alström families if particular muta-
tions were associated with more severe cardiac fibrosis. In
addition, requests for genetic tests for the syndrome will
come from a wide range of specialists including adult dia-
betologists, ophthalmologists, clinical geneticists, lipid
experts and paediatric endocrinologists. Our results
would support advice to referring clinicians to perform
baseline cardiac MR on patients who screened positive for
mutations in the ALMS1 gene.
Cardiomyopathy is a frequent cause of early mortality in
Alström patients. While the syndrome remains incom-
pletely understood, consistent findings were found
throughout this patient group, which may give insights
into the underlying cardiac pathology. There was no fluid
or fatty infiltration of the myocardium in any patient and
all displayed patchy left and right ventricular fibrosis and
impaired left and right ventricular function, to varying
degrees. Cardiac magnetic resonance imaging not only
provides pathological insights, but gives the opportunity
to detect early functional changes, track the natural his-
tory and progression of the disease, and assess the influ-
ence of therapeutic interventions, as well as guide referral
for transplantation in this challenging group.
It seems likely that any cardiac pathological process in
Alström patients will occur at the microscopic and micro-
circulatory level in a diffuse pattern. Detecting such
changes, even using CMR, is extremely challenging and
many of the features we have described are subtle. As tech-
nology advances and future patients have serial CMR
scans, more information on pathophysiology should
emerge.
Conclusion
This study describes the first results of cardiac magnetic
resonance imaging in this rare population. Confirmation
of ALMS1 gene mutations in a patient is a strong indica-
tion for cardiac magnetic resonance imaging to be per-
formed and for treatment of risk factors for coronary
atherosclerosis.Orphanet Journal of Rare Diseases 2009, 4:14 http://www.ojrd.com/content/4/1/14
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